Home
ALXO
ALXO News

Latest ALX Oncology Holdings Inc. (ALXO) News on November 26, 2025

ALX Oncology to Present at Upcoming Investor Conferences

GlobeNewswire

7 days ago

ALX Oncology to Present at Upcoming Investor Conferences

ALX Oncology Holdings Inc (ALXO) Q3 2025 Earnings Call Highlights: Promising Clinical Advances ...

GuruFocus.com

18 days ago

ALX Oncology Holdings Inc (ALXO) Q3 2025 Earnings Call Highlights: Promising Clinical Advances ...

ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting

GlobeNewswire

a month ago

ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting

ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

GlobeNewswire

a month ago

ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

Is Alnylam Pharmaceuticals (ALNY) Outperforming Other Medical Stocks This Year?

Zacks

a month ago

Is Alnylam Pharmaceuticals (ALNY) Outperforming Other Medical Stocks This Year?

ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire

2 months ago

ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer

GlobeNewswire

2 months ago

ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer

ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

GlobeNewswire

6 months ago

ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

MT Newswires

6 months ago

UBS Adjusts Price Target on ALX Oncology Holdings to $1 From $1.20, Maintains Buy Rating

ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event

GlobeNewswire

6 months ago

ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

GlobeNewswire

6 months ago

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire

7 months ago

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

GlobeNewswire

7 months ago

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

MT Newswires

7 months ago

UBS Adjusts ALX Oncology Price Target to $1.20 From $2.20, Maintains Buy Rating

ALX Oncology’s CD47-blocker and Keytruda combo fails in two Phase II trials

Clinical Trials Arena

7 months ago

ALX Oncology’s CD47-blocker and Keytruda combo fails in two Phase II trials

MT Newswires

7 months ago

ALX Oncology Phase 1/2 Evorpacept Trial to Treat B-cell Non-Hodgkin Lymphoma Shows Anti-tumor Activity

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

GlobeNewswire

7 months ago

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

MT Newswires

7 months ago

ALX Oncology's Phase 2 Trials of Evorpacept, Keytruda Combination in Head, Neck Cancers Fail to Meet Primary Endpoints

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

GlobeNewswire

7 months ago

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate

GlobeNewswire

8 months ago

ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate

ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Zacks

8 months ago

ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Why ALX Oncology Holdings Inc. (ALXO) Soared on Thursday

Insider Monkey

9 months ago

Why ALX Oncology Holdings Inc. (ALXO) Soared on Thursday

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

GlobeNewswire

9 months ago

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

MT Newswires

9 months ago

Jefferies Upgrades ALX Oncology to Buy From Hold, Adjusts Price Target to $3 From $2

MT Newswires

9 months ago

ALX Oncology to Cut Workforce by 30% to Support New Clinical Initiatives

ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

GlobeNewswire

9 months ago

ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

GlobeNewswire

9 months ago

ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

February 2025 US Penny Stocks With Promising Prospects

Simply Wall St.

9 months ago

February 2025 US Penny Stocks With Promising Prospects

ALX Oncology to Host Virtual R&D Day on March 5, 2025

GlobeNewswire

9 months ago

ALX Oncology to Host Virtual R&D Day on March 5, 2025

MT Newswires

10 months ago

UBS Cuts Price Target on ALX Oncology Holdings to $2.20 From $4, Keeps Buy Rating

ALX Oncology Shares Drop 15% Following Positive Phase 2

GuruFocus.com

10 months ago

ALX Oncology Shares Drop 15% Following Positive Phase 2

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

GlobeNewswire

10 months ago

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

GlobeNewswire

10 months ago

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

MT Newswires

10 months ago

Sector Update: Health Care

MT Newswires

10 months ago

ALX Oncology Names New CFO; Shares Rise

ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors

GlobeNewswire

10 months ago

ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors

ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI

GlobeNewswire

10 months ago

ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI

3 US Penny Stocks With Market Caps Under $100M To Watch

Simply Wall St.

a year ago

3 US Penny Stocks With Market Caps Under $100M To Watch

Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?

Zacks

a year ago

Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?

ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

a year ago

ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

MT Newswires

a year ago

Sector Update: Health Care

MT Newswires

a year ago

Top Midday Decliners

MT Newswires

a year ago

ALX Oncology Shares Fall After Downgrade From Jefferies

Investing.com

a year ago

Alx Oncology shares down in pre-market as Jefferies downgrades stock to 'hold'

MT Newswires

a year ago

Jefferies Downgrades ALX Oncology to Hold From Buy, Cuts Price Target to $2 From $12

ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

GlobeNewswire

a year ago

ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024

GlobeNewswire

a year ago

ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024

ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer

GlobeNewswire

a year ago

ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer

3 US Penny Stocks With Market Caps Over $30M To Consider

Simply Wall St.

a year ago

3 US Penny Stocks With Market Caps Over $30M To Consider

ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference

GlobeNewswire

a year ago

ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference

ALX Oncology Holdings (ALXO) Loses -27.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

a year ago

ALX Oncology Holdings (ALXO) Loses -27.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

GlobeNewswire

a year ago

ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

ALX Oncology Announces November Investor Conference Participation

GlobeNewswire

a year ago

ALX Oncology Announces November Investor Conference Participation

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024

GlobeNewswire

a year ago

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024

Millennium Management LLC Reduces Stake in ALX Oncology Holdings Inc

GuruFocus.com

a year ago

Millennium Management LLC Reduces Stake in ALX Oncology Holdings Inc

ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference

GlobeNewswire

a year ago

ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference

ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi

GlobeNewswire

a year ago

ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi

MT Newswires

a year ago

UBS Adjusts Price Target on ALX Oncology to $4 From $25, Maintains Buy Rating

ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

GlobeNewswire

a year ago

ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients

Benzinga

a year ago

Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients

MT Newswires

a year ago

Top Premarket Decliners

ALX Oncology’s evorpacept shows potential in Phase II gastric cancer trial

Clinical Trials Arena

a year ago

ALX Oncology’s evorpacept shows potential in Phase II gastric cancer trial

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

GlobeNewswire

a year ago

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

GlobeNewswire

a year ago

ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data

Zacks

a year ago

IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data

Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag

Zacks

a year ago

Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag

Dianthus (DNTH) Gains 18% in the Past Month: Here's Why

Zacks

a year ago

Dianthus (DNTH) Gains 18% in the Past Month: Here's Why

Roche (RHHBY) Receives FDA Nod for Vabysmo Prefilled Syringe

Zacks

a year ago

Roche (RHHBY) Receives FDA Nod for Vabysmo Prefilled Syringe

Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals

Zacks

a year ago

Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals

Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates

Zacks

a year ago

Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates

Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study

Zacks

a year ago

Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study

Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag

Zacks

a year ago

Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag

Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug

Zacks

a year ago

Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug

PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug

Zacks

a year ago

PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug

Merck's (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote

Zacks

a year ago

Merck's (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote

Dr. Reddy's (RDY) to Acquire Haleon's Nicotine Addiction Drug

Zacks

a year ago

Dr. Reddy's (RDY) to Acquire Haleon's Nicotine Addiction Drug

Novo Nordisk's (NVO) Hypertension Drug Study Fails to Meet Goal

Zacks

a year ago

Novo Nordisk's (NVO) Hypertension Drug Study Fails to Meet Goal

ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why

Zacks

a year ago

ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why

Novo Nordisk (NVO) to Invest $4.1B in Clayton Facility Expansion

Zacks

a year ago

Novo Nordisk (NVO) to Invest $4.1B in Clayton Facility Expansion

Alnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals

Zacks

a year ago

Alnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals

Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer

Zacks

a year ago

Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer

JAZZ Falls as Suvecaltamide Tremor Study Fails to Meet Goals

Zacks

a year ago

JAZZ Falls as Suvecaltamide Tremor Study Fails to Meet Goals

Day One (DAWN) In-Licenses MabCare Cancer Candidate, Stock Up

Zacks

a year ago

Day One (DAWN) In-Licenses MabCare Cancer Candidate, Stock Up

Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals

Zacks

a year ago

Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals

Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals

Zacks

a year ago

Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 06/18/2024

Insider Buying: CFO Peter Garcia Acquires Shares of ALX Oncology Holdings Inc (ALXO)

GuruFocus.com

a year ago

Insider Buying: CFO Peter Garcia Acquires Shares of ALX Oncology Holdings Inc (ALXO)

Shattuck (STTK) Announces Positive Interim Data on Cancer Drug

Zacks

a year ago

Shattuck (STTK) Announces Positive Interim Data on Cancer Drug

Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study

Zacks

a year ago

Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study

Geron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up

Zacks

a year ago

Geron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up

ChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag

Zacks

a year ago

ChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag

Moderna (MRNA) Submits Updated COVID-19 Jab to FDA for Review

Zacks

a year ago

Moderna (MRNA) Submits Updated COVID-19 Jab to FDA for Review

Replimune (REPL) Gains on Positive Data From Melanoma Study

Zacks

a year ago

Replimune (REPL) Gains on Positive Data From Melanoma Study

Halozyme (HALO) Raises 2024 Financial Guidance, Stock Up 13%

Zacks

a year ago

Halozyme (HALO) Raises 2024 Financial Guidance, Stock Up 13%

Vir Biotechnology (VIR) Up on Positive Data From HDV Study

Zacks

a year ago

Vir Biotechnology (VIR) Up on Positive Data From HDV Study

Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals

Zacks

a year ago

Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals

Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo (Revised)

Zacks

a year ago

Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo (Revised)

Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study

Zacks

a year ago

Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study

Share on Social Networks: